Waxaan codsanaa saynis-goyn si aan u abuurno daawayn cusub oo wanaajin doona nolosha kuwa la ildaran kansarka, xanuunka aan la kabi karin iyo COVID-19.
Kansarka hidde ahaan waa kala duwan yahay, aad u laqabsan karo, si joogto ah isu beddelaya oo aan la arki karin habka difaaca jirka. Habkayaga daawaynta kansarka waxay ku salaysan tahay aaminsanaanta in bukaanadu u baahan doonaan habab badan oo kala duwan, hab isku dhafan - bartilmaameedka hal ama kala duwan ee bartilmaameedyada gacanta iyo weerarida kuwa dhowr weji ah - isku mar ama si isdaba joog ah, si joogta ah oo aan naxariis lahayn.
Habka aan ula dagaalanno kansarka waxaa suurtageliyay faylalka difaaca jirka ee gaarka ah (“IO”), oo ka kooban noocyo badan oo hanti cusub oo cusub, sida maktabad buuxda oo biniaadmi ah (“G-MAB™”) in iskood loo isticmaalo ama lagu daro habab beegsiga kansarka oo ay ku jiraan:
Hantidaas waxa kaaba qalab la beegsanayo lenmfatic (Sofusa®) loogu talagalay in lagu gaarsiiyo unugyada difaaca jirka nidaamka lymfatic, halkaas oo unugyada difaaca jirka lagu tababaro la dagaalanka kansarka.
Waxaan ka soo saarnay unugyada difaaca jirka ee ka dhanka ah bartilmaameedyo badan oo muhiim u ah daaweynta kansarka, oo ay ku jiraan PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, iyo bartilmaameedyo kale oo badan, kuwaas oo ku jira heerar kala duwan oo horumarineed. Barnaamijyadayada CAR-T waxaa ka mid ah heerka bukaan-socodka CD38 CAR T. Daawaynta isku darka hababka waxay ku jiraan qiimeynta marxaladda hore ee myeloma badan, kansarka sambabada, iyo kansarka kale ee qaangaarka iyo carruurta.
- CAR T (Chimeric Antigen Reseptor – T Cells) therapy kaas oo wax ka beddelaya unugyada T ee bukaanka si ay u dilaan burada
- DAR T (Dimeric Antigen Reseptor – T Cells) teraabiyada wax ka beddeleysa unugyada T-deeqaha ee deeqaha caafimaadka qaba si ay uga falceliyaan buro kasta oo bukaan ah, taas oo u oggolaanaysa in “ka baxsan shelf” lagu daweeyo buro bukaanka
- Conjugates-ka-hortagga-Drug-ga ("ADCs"), iyo
- Barnaamijyada Virus-ka Oncolytic (Seprehvir™, Seprehvec™)
"Portfolio-ga gaarka ah ee hantida madal IO waa mid aan lala tartamin warshadaha. Waxaa ka mid ah xakameynta isbaarada difaaca, unugyada bispecific antibodies, conjugates antibody-drug conjugates (ADCs) iyo sidoo kale chimeric antigen reseptor (CAR) iyo dimeric antigen receptor (DAR) daawaynta gacanta ku salaysan, iyo dhawaanahan waxaan ku darnay fayrasyada oncolytic (Seprehvir ™, Seprehvec). ™). Hanti kasta si gaar ah ayaa muujinaysa ballanqaad weyn; Isku soo wada duuboo waxaan dareemaynaa inay awood u leeyihiin inay ka gudbaan caqabadaha ugu adag ee kansarka "
– Dr. Henry Ji, CEO
Ballanqaadkayaga ah inaan hagaajino nolosha bukaanka waxa hadda loo maleynayo inay tahay xanuunka aan la dabooli karin ayaa sidoo kale lagu muujiyay dadaalkayaga aan joogtada ahayn ee lagu horumarinayo fasalka koowaad ee fasalka (TRPV1 agonist) oo aan ahayn opioid molecule yar yar, Resiniferatoxin ("RTX").
Resiniferatoxin waxay awood u leedahay inay si qoto dheer u bedesho habka loo maareeyo xanuunka ee calaamado kala duwan, sababtoo ah saameynta xoogga leh iyo muddada dheer ee hal-abuurka ah laakiin sidoo kale sababtoo ah faa'iidooyinka muuqaalkeeda aan-opioid.
RTX waxay dhamaystiraysaa tijaabooyinka hore ee muhiimka ah ee calaamadaha bini'aadamka sida osteoarthritis iyo dhamaadka xanuunka kansarka nolosha, iyada oo daraasadaha diiwaangelinta muhiimka ah loo qorsheeyay inay bilaabaan qeybtii labaad ee 2020.
RTX waxay sidoo kale ku jirtaa tijaabooyinka muhiimka ah ee codsiga eeyaha saaxiibka ah ee ay adagtahay in la maareeyo xusulka arthritic. Maaddaama xayawaanku ay qayb ka yihiin qoyska, habkayaga horumarinta xalalka maaraynta xanuunka ee cusub waxaa loola jeedaa in lagu daro noocyada kale ee aan jecelnahay!